Recent Quotes (30 days)

You have no recent quotes
chg | %

Knight Therapeutics Inc  

(Public, CVE:GUD)   Watch this stock  
Find more results for GUD
6.14
Apr 28 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 3.51 - 7.24
Open     -
Vol / Avg. 0.00/822,875.00
Mkt cap 138.83M
P/E     -
Div/yield     -
EPS 0.00
Shares     -
Beta     -
Inst. own     -
Mar 19, 2015
Q4 2014 Knight Therapeutics Inc Earnings Call
Mar 19, 2015
Q4 2014 Knight Therapeutics Inc Earnings Release
  

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 114023.80% 34451.68%
Operating margin -2203.51% -1258.19%
EBITD margin - -1234.87%
Return on average assets 134.00% -
Return on average equity 135.57% -
CDP Score - -

Address

Suite 102, 6111 Royalmount Avenue
MONTREAL, QC H4P 2T4
Canada
+1-514-3401112 (Phone)
+1-514-3444675 (Fax)

Website links

Description

Knight Therapeutics Inc. (Knight) is a specialty pharmaceutical company. The Company is focused on developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products. The Company�s product pipeline consists of the product Impavido (miltefosine), an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. Impavido is an oral agent indicated for the treatment of visceral and cutaneous leishmaniasis and was included in the World Health Organization (WHO) essential medicines list as an anti-leishmaniasis medicine.

Officers and directors

Jonathan Ross Goodman President, Chief Executive Officer, Director
Age: 46
Jeffrey Kadanoff Chief Financial Officer
Amal Khouri Vice President - Business Development
James C. Gale Director
Age: 64
Robert N. Lande Director
Age: 51
Edward J. Schutter Director
Age: 63
Sylvie Tendler Director